ClinicalTrials.gg
TerminatedNCT04825860Updated Mar 15, 2024

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

A Phase 2/3 interventional study of SEP-363856 50 mg and SEP-363856 75 mg in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Terminated at 54 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Due to company business strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
12th of 23
83 · median 83
Started
2021
with 1 other
Phase 2/3
Only one
of the 23
Registered
13th of 23
by date
Lead sponsor
4 of 23
Sumitomo Pharma Co., Ltd.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 12th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 2/3, and was the 13th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.

Read the detailed description

A Phase 2/3 Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase.

The double-blind phase is to evaluate the efficacy and safety of 2 doses of SEP-363856 (50 and 75 mg/day) versus placebo over 6 weeks in acutely psychotic patients with schizophrenia. This phase is projected to randomize approximately 480 subjects to 3 treatments (SEP-363856 50 mg/day, SEP-363856 75 mg/day, placebo) in a 1:1:1 ratio. The completers of the double-blind phase will be able to enroll into the 12-week open-label phase during which the long term safety and effectiveness of-SEP 363856 will be evaluated.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be fully informed of and understand the objectives, procedures, and possible benefits and risks of the study, and give written prior to performing any study related activities. If the subject is considered a minor according to local regulations at the time of collection of the informed consent, written consent will be obtained from a legally acceptable representative (guardian) in addition to that obtained from the subject.
  2. Male or female between 18 to 65 years of age (inclusive) at the time of consent.
  3. Must meet DSM 5 criteria for schizophrenia as established by clinical interview at Screening
  4. Must have a CGI S score ≥ 4 (moderately ill) at Screening and Baseline.
  5. Must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions (P1), conceptual disorganization (P2), hallucinations (P3), and unusual thought content (G9) at Screening and Baseline.
  6. Must have an acute exacerbation of psychotic symptoms (no longer than 2 months prior to providing informed consent for this study). The acute exacerbation should include:

    a. Marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.

  7. In the opinion of the Investigator, subjects must be generally healthy based on Screening medical history, physical examination (PE), vital signs, , and clinical laboratory values (hematology, chemistry, and urinalysis).

Exclusion criteria

Exclusion Criteria:

  1. Have a DSM 5 diagnosis or presence of symptoms consistent with a DSM 5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment
  2. At significant risk of harming self, others, or objects based on Investigator's judgment.
  3. Have any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
  4. Female subjects who are pregnant or lactating.
  5. Have any clinically significant abnormal laboratory value(s) at Screening (hematology, chemistry, and urinalysis) as determined by the Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    SEP-363856 50 mg/day

    Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.

    Drug: SEP-363856 50 mg

  • Experimental
    SEP-363856 75 mg/day

    Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.

    Drug: SEP-363856 75 mg

  • Placebo comparator
    Placebo

    Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.

    Drug: Placebo

Interventions

  • Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

  • Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

  • DrugPlacebo

    Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Week 6

    PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

    Time frame: Week 6

Secondary outcomes

  1. Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Week 6

    The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

    Time frame: Week 6

07

Study locations

54 sites
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing, China
  • Peking University Sixth Hospital
    Beijing, Beijing, China
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • The Second People's Hospital of Hunan Province/ Brain Hospital of Hunan Province
    Changsha, Hunan, China
  • Shandong Daizhuang Hospital
    Jining, Shandong, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai, China
  • The Mental Health Center of Xi'an
    Xian, Shanxi, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin, China
  • Hotei Hospital
    Konan, Aichi, Japan
  • Okehazama Hospital Fujita Kokoro Care Center
    Toyoake, Aichi, Japan
  • Medical corporation Seijinkai Seinan Hospital
    Hachinohe, Aomori, Japan
  • Kohnodai Hp., National Center for Global Health and Medicine
    Ichikawa, Chiba, Japan
  • Shiranui Hospital
    Omuta, Fukuoka, Japan
  • Juzenkai Oorin Hospital
    Onojo, Fukuoka, Japan
  • Takeda General Hospital
    Aizu-Wakamatsu, Fukushima, Japan
  • Mihara Hospital
    Mihara, Hiroshima, Japan
  • Fujimidai Hospital
    Hiratsuka, Kanagawa, Japan
  • Okinawa Tokushukai Hino Hospital
    Yokohama, Kanagawa, Japan
  • Yatsushiro Kosei Hospital
    Yatsushiro, Kumamoto, Japan
  • Miyakonojo Shinsei Hospital
    Miyakonojo, Miyazaki, Japan
  • Shonan Hospital
    Matsumoto, Nagano, Japan
  • Mental Support Soyokaze Hospital
    Ueda, Nagano, Japan
  • NHO Ryukyu Hospital
    Kunigami, Okinawa, Japan
  • Social welfare corporation Tenshinkai Kosaka hospital
    Higashiosaka, Osaka, Japan
  • Kansai Medical University Medical Center
    Moriguchi, Osaka, Japan
  • Nishiurakai Keihan Hospital
    Moriguchi, Osaka, Japan
  • Neyagawa Sanatorium
    Neyagawa, Osaka, Japan
  • Asakayama Hospital
    Sakai, Osaka, Japan
  • Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital
    Takatsuki, Osaka, Japan
  • NHO Hizen Psychiatric Center
    Kanzaki, Saga, Japan
  • Rainbow & Sea Hospital
    Karatsu, Saga, Japan
  • Nishi Kumagaya Hospital
    Kumagaya, Saitama, Japan
  • Shiga university of medical science hospital
    Otsu, Shiga, Japan
  • Negishi Hospital
    Fuchu, Tokyo, Japan
  • Narimasu Kosei Hospital
    Itabashi, Tokyo, Japan
  • National Center of Neurology and Psychiatry
    Kodaira, Tokyo, Japan
  • National Hospital Organization Hokuriku National Hospital
    Nanto, Toyama, Japan
  • Azusakai Kawada Hospital
    Takaoka, Toyama, Japan
  • Sanyokai Sanyo Hospital
    Sakata, Yamagata, Japan
  • Akino Hospital
    Tendo, Yamagata, Japan
  • Akita City Hospital
    Akita, Japan
  • Inokuchi Noma Hospital
    Fukuoka, Japan
  • Kuramitsu Hospital
    Fukuoka, Japan
  • Minkodo Aburayama Hospital
    Fukuoka, Japan
  • Satokai Yuge Hospital
    Kumamoto, Japan
  • Miyazaki Prefectural Miyazaki Hospital
    Miyazaki, Japan
  • Mariveles Mental Wellness and General Hospital
    Mariveles, Bataan, Philippines
  • St. Paul's Hospital of Iloilo, Inc.
    Iloilo City, Iloilo, Philippines
  • Makati Medical Center
    Makati, Metro Manila, Philippines
  • National Center for Mental Health
    Mandaluyong, Metro Manila, Philippines
  • Southern Philippines Medical Center
    Davao, Philippines
  • Chang Gung Memorial Hospital, Keelung
    Keelung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Oct 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 1, 2021
StartActual
Mar 29, 2021
Primary completionActual
Oct 12, 2023
CompletionActual
Oct 19, 2023
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04825860
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Mar 29, 2021
Primary completion
Oct 12, 2023
Completion
Oct 19, 2023
Last update
Mar 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion